Impact Factor 5.511

Among the world's top 10 most-cited Immunology journals

Correction ARTICLE

Front. Immunol., 13 November 2017 | https://doi.org/10.3389/fimmu.2017.01582

Corrigendum: Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins

imageJi-Hee Ha1, imageJung-Eun Kim1 and imageYong-Sung Kim1,2*
  • 1Department of Molecular Science and Technology, Ajou University, Suwon, South Korea
  • 2Department of Applied Chemistry and Biological Engineering, College of Engineering, Ajou University, Suwon, South Korea

A corrigendum on

Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins
by Ha J-H, Kim J-E, Kim Y-S. Front Immunol (2016) 7:394. doi: 10.3389/fimmu.2016.00394

In the original article, there was an error [wrong description on LY3164530 (Eli Lilly) antibody in the last paragraph of page 9 of original article].

A correction has been made to section “HETERODIMERIC Fc-BASED ANTIBODIES IN DIVERSE FORMATS”, subsection “Intact IgG Formats with Correct LC Association”, sixth Paragraph (line 8–12 of the sixth paragraph) (In the last paragraph of page 9 of original article):

An alternative approach for enforcing correct HCVH-CH1–LC association includes introduction of a set of mutations at the heterodimeric VL–CL and VH–CH1 interface (18, 66, 67), similar to modification of the CH3 interface for the heterodimeric Fc design. In an ortho-Fab IgG approach (18), structure-based regional design introduced complementary mutations at the LC and HCVH-CH1 interface in only one Fab, without any changes being made to the other Fab (Figure 3). Zymeworks is currently developing intact IgG-format bsAbs generated by the combination of ortho-Fab IgG and ZW1 Fc technologies (http://www.zymeworks.com/).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: bispecific antibody, Fc engineering, heterodimeric Fc, Fc-fusion proteins, immunocytokines, antibody engineering

Citation: Ha J-H, Kim J-E and Kim Y-S (2017) Corrigendum: Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins. Front. Immunol. 8:1582. doi: 10.3389/fimmu.2017.01582

Received: 19 October 2017; Accepted: 02 November 2017;
Published: 13 November 2017

Edited and Reviewed by: Tianlei Ying, Fudan University, China

Copyright: © 2017 Ha, Kim and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yong-Sung Kim, kimys@ajou.ac.kr